Antipsychotics & Diabetes: Pfizer Highlighting Differences Between Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer will launch its "Metabolics Matter" campaign in June to educate psychiatrists about the risk of diabetes associated with atypical antipsychotic agents.